Volume 7.44 | Nov 12

Cord Blood News 7.44 November 12, 2015
Cord Blood News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   CBN on Twitter
Preclinical Targeting of Human T Cell Malignancies Using CD4-Specific Chimeric Antigen Receptor (CAR)-Engineered T Cells
Investigators designed a CAR, CD4CAR, which re-directs the antigen-specificity of CD8+ cytotoxic T cells to CD4-expressing cells. CD4CAR T cells derived from human peripheral blood mononuclear cells and cord blood effectively redirected T-cell specificity against CD4+ cells in vitro. [Leukemia] Abstract
New Cell Separation Kits to Isolate 90% Pure CD34+ Cells from Cord Blood. See the data and learn more here!
PUBLICATIONS (Ranked by impact factor of the journal)
Direct Conversion of Human Amniotic Cells into Endothelial Cells without Transitioning through a Pluripotent State
Researchers describe a three week platform for directly converting human mid-gestation lineage-committed amniotic fluid-derived cells into a stable and expandable population of vascular endothelial cells without using pluripotency factors. [Nat Protoc] Abstract

Lysophosphatidic Acid Enhances Survival of Human CD34+ Cells in Ischemic Conditions
Scientists showed that lysophosphatidic acid-treated human umbilical cord blood-derived CD34+ cells cultured under hypoxic and serum-deprived conditions present 2.2-fold and 1.3-fold higher survival relatively to non-treated cells and prostaglandin E2-treated cells, respectively. [Sci Rep] Full Article

Mechanical Fibrinogen-Depletion Supports Heparin-Free Mesenchymal Stem Cell Propagation in Human Platelet Lysate
Investigators searched for an efficient and reproducible medium preparation method that avoids clot formation while omitting animal-derived heparin. Bone-marrow and umbilical cord derived mesenchymal stem cells were tested for surface markers by flow cytometry and for trilineage differentiation capacity. [J Transl Med] Full Article

Transplantation of Mesenchymal Stem Cells in a Laryngeal Carcinoma Patient with Radiation Myelitis
Researchers describe the outcome of allogeneic umbilical cord-derived mesenchymal stem cell transplantation in a patient with laryngeal carcinoma who developed radiation-induced myelitis of his spinal cord with characteristic magnetic resonance imaging changes. [Stem Cell Res Ther] Full Article

Evaluation of a Cell-Banking Strategy for the Production of Clinical Grade Mesenchymal Stromal Cells from Wharton’s Jelly
Factors affecting the success of the derivation process (namely, time elapsed from birth to processing and weight of fragments), and methods for establishing a two-tiered system of Master Cell Bank and Working Cell Bank of umbilical cord derived-mesenchymal stromal cells were analyzed. [Cytotherapy] Abstract

A Comparison of Wharton’s Jelly and Cord Blood as a Source of Mesenchymal Stem Cells for Diabetes Cell Therapy
Scientists investigated the differences between mesenchymal stem cells isolated from umbilical cord blood and Wharton’s jelly as sources of diabetes mellitus cell therapy. [Regen Med] Abstract

Effects of Mesenchymal Stromal Cells on Human Myeloid Dendritic Cell Differentiation and Maturation in a Humanized Mouse Model
Investigators used a humanized mouse model to study the immunomodulatory effects of human mesenchymal stromal cells on human dendritic cell immunobiology. Humanized mice were established by injection of cord blood CD34+ cells into NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice. [J Immunol Methods] Abstract

Need a more reliable source of cells? Choose from our range of primary cells. Learn more!
Update on Mesenchymal Stem Cell-Based Therapy in Lupus and Scleroderma
Multipotent mesenchymal stem cells (MSCs), isolated from bone marrow and other sites, display specific immunomodulation and anti-inflammatory properties and appear as ideal tools to treat such diseases. The authors summarize recent knowledge acquired in the field of MSC-based therapies for lupus and scleroderma. [Arthritis Res Ther] Full Article

Visit our reviews page to see a complete list of reviews in the cord blood research field.
Endonovo Therapeutics Files Patent Application on Cell Therapy Created Using Its Proprietary Cell-Enhancing Cytotronics Platform
Endonovo Therapeutics, Inc. announced that it has filed a patent application with the United States Patent and Trademark Office on a perivascular cell mixture created using its proprietary Cytotronics™ Platform that would allow for the wide spread use of cord blood in the treatment of malignant and non-malignant hematological disorders. [Endonovo Therapeutics, Inc.] Press Release

NIH Awards City of Hope $2.2 Million Grant for Study of Chronic Graft-versus-Host Disease
The National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) has awarded a $2.2 million grant to help City of Hope researchers explore the underlying mechanisms of graft-versus-host disease, the leading cause of long-term sickness and death following transplantation of bone marrow cells from a donor. [City of Hope (Business Wire)] Press Release

From our sponsor: 3D intestinal organoid culture is made easy with IntestiCult™. Request a sample.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW The Stem Cell Niche 2016
May 22-26, 2016
Hillerod, The Netherlands

Visit our events page to see a complete list of events in the cord blood community.
NEW Postdoctoral Research Scientist – Immunotherapy Group (The Anthony Nolan Trust)

NEW Faculty Positions – Regenerative Medicine for Organ Regeneration or Transplantation (The University of Texas Medical School at Houston)

Principal Scientist – Hematopoietic Products (STEMCELL Technologies Inc.)

Postdoctoral Fellow – Leukemia Research (City of Hope)

PhD Studentships – Cancer Research (Cancer Research UK Manchester Institute)

Faculty Member – Hematopoietic Cell Transplant (Fred Hutchinson Cancer Research Center)

Hematopoietic Stem Cell Biologist (Mayo Clinic)

Assistant or Associate Professor – Cell and Regenerative Biology (University of Wisconsin, Madison)

Assistant Member – Cord Blood Transplantation (Fred Hutchinson Cancer Research Center)

Postdoctoral Positions – Cancer and Developmental Biology (North Carolina Central University)

Research Associate – Leukemia, Stem Cells and Development (Josep Carreras Leukemia Research Institute)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Cord Blood News: Archives | Events | Contact Us